A Look at Marc Beer, Impacting Lives of Women Affected by Pelvic Floor Disorders

Marc Beer is the co-Founder, Chairman and Chief Executive Officer of Renovia Inc. He has raised $32 million in Series B round and $10 million in venture debt. He is now set to continue with new products for pelvic floor disorders.

 

 

The Renovia Inc. boss’s 25 years of experience in the health care industry goes a long way to give the company the leadership it needs to achieve its goals and objectives. He is specialized in biotechnology, devices, diagnostics as well as pharmaceuticals. He co-founded Renovia with Ramon Iglesias and Yolanda Lorie in 2016.

 

While at his previous company, Marc Beer played a big role in its growth and its product, JUXTAPID, was approved in 36 countries. In 2000, Marc worked with ViaCell as the founding CEO for seven years. Under his leadership, the company grew rapidly and was later acquired by PerkinElmer. While working with ViaCell, Marc was also the board member of Erytech Pharma. Erytech Pharma is a biopharmaceutical company. Additionally, he served in various executive positions in Genzyme, before joining ViaCell. The most recent position at Genzyme includes being the Vice President of Global Marketing. Marc Beer graduated from Miami University in Ohio with a Bachelor of Science degree.

 

 

Currently, Renovia is working to create various diagnostic as well as therapeutic products to help treat pelvic floor disorders such as urinary incontinence. According to researchers, the condition affects about 250 million women across the world. The first product Renovia developed, Leva, was approved by FDA in April.

 

 

The Longwood Fund contributed funds towards Renovia’s efforts to develop and test 4 more therapeutic as well as diagnostic products during the Series B round. Longwood Fund is an investment firm focused in investing in healthcare. The Series B round was under the leadership of Perspective Advisors based in New York as well as Ascension Ventures which is based in Missouri.

 

 

In a statement, Mr.Beer was excited and applauded the support his company was getting from the group of health care investors. He added that the investors shares their vision to better diagnose and treat millions of women affected by the disorders. He said that they will combine their innovative as well as proprietary sensor technologies and form factors with a health platform which is digital provide their customers with valuable data that will lead to development of new treatment options, add to the body of knowledge and enhance understanding of pelvic floor disorders. Eventually, the reduced long-term health care costs will be realized.

 

 

Marc Beer has been working in Renovia since 2015. Before joining Renovia, Beer worked with OvaScience as a strategic consultant. He is an accomplished career man and under his leadership, Renovia is bound to grow and impact more lives positively. Learn more : https://www.slideshare.net/MarcBeer

Marc Beers and Renovia

Renovia Inc., an upstart company co-founded by Marc Beer, the former CEO of Aegerion Pharmaceuticals, has announced that it will be moving forward with a variety of new products for consumers with pelvic floor disorders. These include ailments like urinary incontinence. The first of these products, Leva, gained FDA approval this April.

Beer has worn several hats throughout his long career. Previously, Beer had positions within Genzyme, including Vice President of Global Marketing. He had several marketing and sales jobs within the diagnostic and pharmaceutical branches of Abbot Laboratories. He was a member of the Mass Life Board of the Commonwealth of Massachusetts and served on the Biotechnology Industry Organization Emerging Companies Section Governing Board.

Beer has also been the founding CEO of ViaCell, a company that specializes in the development, preservation, and collection of umbilical cord blood stem cells. While there, he led the company, helping to bring it from a small upstart company and make it into a quickly growing commercial venture. The company would grow to over 300 employees and eventually became a publicly traded company in 2005. Ultimately it would be acquired by Perkin-Elmer. He was also a member of the board of directors of Erytech Pharma.

In addition to these positions, Beers was a member of the Audit committee, chairman of the compensation committee, and Founding chairman of the board of directors for Minerva Neurosciences Inc. Beers was Founding Chairman of the board of directors and chairman of the compensation committee of GoodStart Genetics, Inc. Beer had also previously served as a consultant for OvaScience and was a member of Miami University Business Advisory Council. He was also a member of the Notre Dame Research and Commercialization Advisory Committee and Notre Dame Graduate Studies Research and Advisory Council. Beer has a BS from Miami University in Ohio. Learn more : https://www.slideshare.net/MarcBeer